Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Aranesp Prescribers (US)

Articles with lock require a subscription to GLG News | Request a free trial
July 7, 2008
One Drug Many Uses: Prove It
Analysis of: One drug, many uses. Good idea? | www.indystar.com
Author: Michael Grossbard, Professor of Clinical Medicine, Columbia University College of Physicians and Surgeons
Lilly has devoted substantial energy/expense in developing Cymbalta for many indications.  Is this at the expense of developing novel agents? 
July 7, 2008
Can China Make Generics Better than They Make Toys
Analysis of: China Muscles In On The Generics Industry | www.pharmalot.com
Author: Michael Grossbard, Professor of Clinical Medicine, Columbia University College of Physicians and Surgeons
Several Chinese companies are set to enter the generic drug market ove the next year.  If these agents are demonstrated to be safe, they could have a large impact on the generic drug industry.
July 7, 2008
Avastin Effecitve in Lung and Breast Cancer But is it Cost Effective?
Analysis of: Roche decision denies cancer drug to Britons | www.ft.com
Author: Michael Grossbard, Professor of Clinical Medicine, Columbia University College of Physicians and Surgeons
Roche has elected not to provide information on the cost effectiveness and clinical effectiveness of Avastin in breast cancer to the medicine advisory board of the British government.  As such, the drug will not be able for first line treatment of these diseases in Britain.
July 3, 2008
Lung cancer profiling- May lead to improvements in care! Implications for Genentech & others.
Analysis of: Detection of Mutations in EGFR in Circulating Lung-Cancer Cells | content.nejm.org
Author: GLG Expert Contributor
We may be able to analyze EGFR mutations from periperal blood of lung cancer patients. Very frequently enough tissue fromm needle biopsies are not available for analysis. This may replace the need for new biopsies.
July 3, 2008
Amgen/Oral VEGF Inhibitor/Implications??? Interesting future!
Analysis of: Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer | content.nejm.org
Author: GLG Expert Contributor
This oral Vascular Endothelial Growth Factor (VEGF) inhibitor appears to have activity in radioresistant differentiated thyroid carcinoma.
June 30, 2008
The heck with the impact on Roche. How about the patients??
Analysis of: Roche decision denies cancer drug to Britons | www.ft.com
Author: GLG Expert Contributor
Patients who wish to receive Avastin for breast and lung Cancer will need to pay for it themselves.
June 30, 2008
How are we to pay for computers with a 10% drop in Medicare fees?
Analysis of: Medicare fees to doctors fall Tuesday | news.yahoo.com
Author: GLG Expert Contributor
Rising costs for care of seniors in physician offices will be made more painful by the reimbursement cuts. Will it impede care of seniors??
June 27, 2008
The other shoe falls II: Amgen and J & J will not be happy.
Analysis of: Europe Backs Anemia-Drug Warnings | online.wsj.com
Author: GLG Expert Contributor
Due to possible tumor growth warnings will be attached to the use of erythropoietin agents.
June 26, 2008
Bayer and J &J in the propylactic anticoagulation market. GSK (Lovenox) beware!
Analysis of: Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty | content.nejm.org
Author: GLG Expert Contributor
This paper as well as http://content.nejm.org/cgi/content/full/358/26/2765 report the efficacy of an oral anticoagulant type drug that appears to be better & safer than parenteral low molecular weight heparin (LMWH).
June 23, 2008
Amgen as well as J & J: Adding insult to injury......
Analysis of: New Study Probes Safety of Erythropoiesis-Stimulating Agents | www.medscape.com
Author: GLG Expert Contributor
Safety concerns continue to be voiced re: the effect of erythropoietin products (Epos) on tumor growth.

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Next61 to 70 of 582

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T17:45:17.637